Comparative Pharmacology
Head-to-head clinical analysis: DISPERMOX versus NALLPEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISPERMOX versus NALLPEN IN PLASTIC CONTAINER.
DISPERMOX vs NALLPEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Nallpen is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically active against beta-lactamase-producing Staphylococcus aureus.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
Nafcillin 1-2 g IV every 4 hours for moderate to severe infections; for MSSA bacteremia or endocarditis, 2 g IV every 4 hours.
None Documented
None Documented
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
0.9-1.2 hours; prolonged in renal impairment (up to 7-10 hours in anuria); requires dose adjustment for CrCl <30 mL/min
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Primarily renal (60-80% unchanged drug via glomerular filtration and tubular secretion); biliary/fecal: minor (<5%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic